Abstract
In spite of conventional treatment modalities which include surgery, chemotherapy, and radiotherapy, the survival rates for patients with malignant gliomas remain disappointing. Successful treatment has been limited by difficulties in delivering therapeutic agents to the central nervous system (CNS). Specifically, drug penetration of the blood brain barrier (BBB) poses a unique and challenging problem in glioma therapy. Recently, however, promising techniques have emerged to circumvent this problem. One such advancement is convection-enhanced delivery (CED). This method was originally introduced and refined in the early 1990s by researchers at the National Institute of Health (NIH) and involves drug infusion under high pressure using intracranial catheters. CED allows for delivery of high concentrations of therapeutic agents directly into brain tumors and surrounding parenchyma. This method eludes the BBB and allows the use of regional drug therapy, while at the same time limiting systemic toxicity. In the present article, we review both the preclinical and clinical studies concerning CED. We also discuss future directions and the potential impact of this modality on the treatment of malignant gliomas.
Keywords: Brain tumor, convection-enhanced delivery, malignant glioma, IL4-PE, IL13-PE38, TransMID, Cotara
Current Drug Delivery
Title: Convection Enhanced Drug Delivery of Novel Therapeutic Agents to Malignant Brain Tumors
Volume: 4 Issue: 2
Author(s): Sherise Ferguson and Maciej S. Lesniak
Affiliation:
Keywords: Brain tumor, convection-enhanced delivery, malignant glioma, IL4-PE, IL13-PE38, TransMID, Cotara
Abstract: In spite of conventional treatment modalities which include surgery, chemotherapy, and radiotherapy, the survival rates for patients with malignant gliomas remain disappointing. Successful treatment has been limited by difficulties in delivering therapeutic agents to the central nervous system (CNS). Specifically, drug penetration of the blood brain barrier (BBB) poses a unique and challenging problem in glioma therapy. Recently, however, promising techniques have emerged to circumvent this problem. One such advancement is convection-enhanced delivery (CED). This method was originally introduced and refined in the early 1990s by researchers at the National Institute of Health (NIH) and involves drug infusion under high pressure using intracranial catheters. CED allows for delivery of high concentrations of therapeutic agents directly into brain tumors and surrounding parenchyma. This method eludes the BBB and allows the use of regional drug therapy, while at the same time limiting systemic toxicity. In the present article, we review both the preclinical and clinical studies concerning CED. We also discuss future directions and the potential impact of this modality on the treatment of malignant gliomas.
Export Options
About this article
Cite this article as:
Ferguson Sherise and Lesniak S. Maciej, Convection Enhanced Drug Delivery of Novel Therapeutic Agents to Malignant Brain Tumors, Current Drug Delivery 2007; 4 (2) . https://dx.doi.org/10.2174/156720107780362302
DOI https://dx.doi.org/10.2174/156720107780362302 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biocompatible Targeting Hydrogels for Breast Cancer Treatment
Mini-Reviews in Medicinal Chemistry Transferrin Coupled Liposomes for Enhanced Brain Delivery of Doxorubicin
Vascular Disease Prevention (Discontinued) Carbon Nanotube: A Versatile Carrier for Various Biomedical Applications
Drug Delivery Letters Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Recent Developments in the Chemical Biology of Epothilones
Current Pharmaceutical Design Preclinical Evidence on the Anticancer Properties of Food Peptides
Protein & Peptide Letters LncRNA HOTAIR Polymorphisms Association with Cancer Susceptibility in Different Tumor Types
Current Drug Targets Aurora-B Kinase Inhibitors for Cancer Chemotherapy
Mini-Reviews in Medicinal Chemistry Carbonic Anhydrase Inhibitors as Anticonvulsant Agents
Current Topics in Medicinal Chemistry Perfusion Computed Tomography and its Application in Oncologic Practice
Current Molecular Imaging (Discontinued) Targeting Poly (ADP) Ribose Polymerase I (PARP-1) and PARP-1 Interacting Proteins for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers
Recent Patents on Anti-Cancer Drug Discovery EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets Fgf10: A Paracrine-Signaling Molecule in Development, Disease, and Regenerative Medicine
Current Molecular Medicine Mechano-Regulation of Alternative Splicing
Current Genomics How Recent Advances in High-risk Myelodysplastic Syndrome Physiopathology May Impact Future Treatments
Current Pharmaceutical Design Nanoparticle Coated Viral Vectors for Gene Therapy
Current Biotechnology Aptamers: Selection, Modification and Application to Nervous System Diseases
Current Medicinal Chemistry Hexokinase II: The Integration of Energy Metabolism and Control of Apoptosis
Current Medicinal Chemistry The Role of Amitriptyline in the Management of Non-small Cell Lung Cancer
Current Cancer Therapy Reviews